DE10111049A1 - Cosmetic or dermatological preparations for combating inflammatory disorders or dryness of the skin, containing agents inhibiting the onset of nitrogen monoxide synthase activity - Google Patents

Abstract

The use of agents (I) which inhibit the onset of nitrogen monoxide (NO) synthase activity in warm-blood organisms is claimed in the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions (including eczema) and/or protecting the skin against dryness determined by sensitivity.

Description

The present invention relates to the use of substances which prevent the NO synthase of the warm-blooded organism unfolds its effect, for the production of cosmetic or dermatological preparations for the prophylaxis and treatment development of inflammatory skin conditions and / or skin protection in sensitive determinants dry skin.

Furthermore, the invention relates to the use of such active ingredients and preparations, sol containing active ingredients, for the immune stimulation of the skin, advantageously also for im Munstimulation in terms of a treatment of the injured skin, especially for Be treatment of wounds.

In addition, the invention relates to preparations with extremely low so-called "Stinging potential".

The skin, especially the epidermis, is as a barrier organ of the human organ in particular external influences. After today's wis Scientific understanding represents the skin an immunological organ, as immunocompetent peripheral compartment plays its own role in inductive, effective and regulatory immune processes of the whole organism.  

The epidermis is rich with nerves and nerve endings such as Father Pacini lamellae bodies, Merkel cell neurite complexes, and free nerve endings for pain, Cold, heat sensation and itching equipped.

Immunosuppression in general is the suppression or attenuation of the reac immune system. Immunosuppression can be local and systemic Ef broken down. Ultimately, it covers a multitude of different aspects, which are all a reduction of the normal immunological defense mechanisms of the Skin include.

For people with sensitive, sensitive or vulnerable skin, one with "Stinging" (<engl. <to sting = injure, burn, hurt) called neurosensory Phenomenon are observed. This "sensitive skin" is fundamentally different of "dry skin" with thickened and hardened horny layers.

Typical reactions of "stinging" to sensitive skin are redness, tightness and burning skin and itching.

As a neurosensory phenomenon is the itching in atopic skin, as well as Itching in skin diseases.

"Stinging" phenomena can be considered to be cosmetically treatable disorders become. On the other hand, severe itching, especially strong atopic skin damage can also be described as a more serious dermatological disorder.

Typical associated with the terms "stinging" or "sensitive skin" disturbing neurosensory phenomena are skin redness, tingling, tingling, Tensing and burning of the skin and itching. You can stimulate by stimulating conditions of use z. B. Massage, Tensideinwirkung, weather influence such as sun, cold, Dryness, but also moist heat, heat radiation and UV radiation, z. B. the Sun, to be evoked.

In "Journal of the Society of Cosmetic Chemists" 28, pp. 197-209 (May 1977) P. J. Frosch and A. M. Kligman a method for estimating the "stinging potential" topically administered substances. As positive substances are here z. For example, lactic acid  and pyruvic acid used. But when measuring by this method were also Amino acids, in particular glycine, determined as neurosensory active (such Substan zen are called "stinger").

According to previous findings occurs such sensitivity to be completely be individually tuned substances differently. This means a person at Contact with a substance experienced "stinging effects", it is highly likely experience repeatedly at each additional contact. The contact with other "stingers" can but just as without any reaction.

Many more or less sensitive people also have some when using deodorant or antiperspirant preparations under erythematous Skin symptoms to suffer.

Erythematous skin manifestations also occur as a side effect in certain Skin disorders or irregularities. For example, the typical skin rash in the appearance of acne regularly more or less reddened.

It was therefore the object of the present invention to overcome the disadvantages of the prior art Technique to remedy.

In particular, active ingredients and preparations containing such active ingredients, should cosmetic and dermatological treatment and / or prophylaxis of erythematous, inflammatory, allergic or autoimmune reactive phenomena, in particular Der matose, but also the appearance of the "Stinging" provided the.

Furthermore, such active ingredients, or preparations containing such active ingredients should, for Are provided, which for immune stimulation of the skin, while beneficial also for immune stimulation in the sense of the wound healing promoting effect used can be.

The endothelium of the blood vessels has a strategic anatomical position between the circulating blood and the underlying vascular muscle cells and thus has  the possibility of both the function of platelets, as well as smooth vessel regulate muscle cells.

An important mediator of this function is Endothelial Nitric Oxide (EDNO), which is formed via a constitutive NO synthase (eNOS) from L-arginine. NO is a gaseous radical and reacts quickly with other substances. Its half-life in biological systems is therefore usually only a few seconds. EDNO is released both luminally and abluminally. The luminal release deactivates platelets and thus prevents the adhesion and Agregregation of these cells. As a result of abluminal release, NO in vascular smooth muscle cells causes vasodilation, which, as in other cells, is mediated by activation of soluble guanylate cyclase and formation of cyclic GMP (cGMP). Finally, the cGMP decreases the intracellular calcium concentration and dephosphorylates the myosin light chain in the vascular smooth muscle cells, causing effective dilatation. EDNO is continuously released from the vessel wall (basal release). The shear forces of the circulating blood and a number of substances such as acetylcholine, bradykinin, substance P and, above all, thrombocytes released from thrombocytes, such as adenine di- and triphosphate and serotonin, additionally increase the release of EDNO (stimulated release).

Today's idea of the relaxing processes in the blood vessels is in progress standing scheme reproduced. A substance A binds to the receptor R one Endothelial cell, which increases the absorption of calcium ions. The elevated cal concentration increases the activity of the enzyme nitric oxide synthase (= NO- Synthase = NOS), which consists of the amino acid L-arginine with simultaneous formation of Citrulline NO releases. This diffuses to the smooth muscle cells, where it is Activated enzyme guanylyl cyclase. This increases the concentration of cGMP, which triggers other processes that lead to muscle relaxation.

According to the invention, the evils of the prior art are eliminated by the Use of substances that prevent the NO synthase of the warm-blooded Organism unfolds its effect, for the production of cosmetic or dermatological Preparations for the prophylaxis and treatment of inflammatory skin conditions - also atopic eczema and / or skin protection in susceptible, determined tro skin.

When using the substances used in the invention or cosmetic or topical dermatological preparations with an effective content of erfindungsge According used substances is an effective treatment, but also a prophylaxis of inflammatory skin conditions - including atopic dermatitis - and / or to the skin protection for sensitive, determined dry skin possible. The invention Substances or cosmetic or topical dermatological preparations with egg The effective content of the active substance according to the invention, however, also serves in over surprisingly to soothe sensitive or irritated skin.

The substance or substances which prevent the NO synthase of the warm-blooded organism from exerting its effect can be advantageously chosen

• a) from the group of substances that inhibits NO synthase (= NO synthase In hibitors or NO synthase inhibitors) and / or
• b) from the group of substances that express the expression of NO synthase in warm-blood organism inhibits or prevents it.

The one or more mentioned under (a) NO synthase inhibitors can be advantageously selected according to the invention from the group comprising: Ebselen (2-phenyl-1,2-benzisosele nazol-3 (2H) -one), canavanine (2 Amino-4-guanidinooxybutyric acid), N-acylsphingosine; 2-amino-4-methylpyridine, S-methylisothiourea, citrulline, thiocarbamate, iminopiperidine, dialkyliminopyridoline, 2-aminopyridine or iminopiperidine, 5-hetero-2-iminohexahydroaze pin, fluoroacetamidine amino acids, oleic acid], aminoguanidine hemisulfate (CAS No .: [996-19-01]), (±) -2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine hydrochloride (CAS No .: [21463-31-0]), Benzamide (CAS No .: [55-21-0]), carboxy-PTIO potassium (2- (4-carboxyphenyl) -4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazol-yloxy 3-oxide potassium) (CAS No .: [148819-94-7]), N ^G , N ^G -dimethyl-L-arginine dihydrochloride (CAS No .: [65005-57-4]), diphenylene iodonium chloride (CAS No .: [244-54-2]), LN ⁵ - (1-iminoethyl) ornithine hydrochloride, (GAS No .: [36889-13-1]), L-N6- (1-iminoethyl) lysine hydrochloride (CAS No .: [150403-89-7]), 1,5-isoquinolinediol (CAS No .: [5154-02-9]), N ^G -monomethyl-L-arginine acetate (CAS) No .: [17035-90-4]), N ^G -nitro-L-arginine (CAS No .: [2149-70-4]), N ^G -nitro-L-arginine methyl ester hydrochloride (CAS No .: [51298-62-5]), 7- Nitroindazole (CAS No .: [2942-42-9]), 1H- [1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (CAS No .: [41443-28-1 ]), 1- (2-trifluoromethylphenyl) imidazole (CAS No .: [25371-96-4]), (25,4R) -4-methylglutamic acid (CAS No .: [31137-74-3]) , 3-bromo-7-nitroindazole (CAS No .: [74209-34-0]), curcumin (1,7-bis (4-hydroxy-3-methoxyphenyl) -1,6-heptadiene-3,5- dion) (CAS No .: [458-37-7]), 6,7-dimethyltetrahydropterin hydrochloride (CAS No .: [167423-51-0]), diphenyleniodonium chloride (CAS No .: [4673-26 -1]), N-ethyl-N'-phenylguanidine hydrochloride, α-guanidinoglutaric acid (CAS No .: [73477-53-9]), S-isopropylisothiourea hydrobromide (CAS No .: (4269-97-0) ), N ^G , N ^G -dimethyl-L-arginine hydrochloride, S-methyl-L-thiocitrulline hydrochloride, L-NIL dihydrochloride (N ⁶ - (iminoethyl) -L-lysine dihydrochloride) (CAS No .: [159190- 45-1]), L-NIO dihydrochloride (N ⁵ - (1-iminoethyl) -L-ornithine dihydrochloride) (CAS No .: [36889-13-1]), L-NMMA citrate (N ⁵ - [1 -imino (methylamino) methyl] -L-arginine citrate), 7-nitroindole (CAS No .: [294 2-42-9]), 1,4-PBIT dihydrobromide (thiocarbamic acid-1,4-phenylenedi-2,1-ethane diyl ester dihydrobromide) (CAS No .: [157254-60-9]), 1,3- PBIT dihydrobromide (thiocarbamimidic acid-1,3-phenylenedi-2,1-ethanediyl ester dihydrobromide), 1- (2-benzoxazolyl) guanidine, nitroguanidine, 1,3-diaminoguanidine, (2-benzothiazolyl) guanidine, 3-bromo Nitroindazole, S-methylthiourea, Norharman, Oregonin, Hirsutanonol.

The inhibitor (s) mentioned under (b) of the inducible NO-Syn For example, thase can be advantageously selected from the group ubiquinone Q10, benzoquinones, dexmethasone (11β, 16α) -9-fluoro-11,17,21-trihydroxy-16-methylpreg na-1,4-diene-3,20-dione).  

Preferred NO synthase inhibitor is nitroarginine. Its chemical structure is characterized as follows:

Cosmetic or dermatological preparations according to the invention preferably contain 0.001-10 wt .-%, particularly preferably 0.01-1 wt .-%, of one or more meh substances that prevent the NO synthase of the warm-blooded organism unfolds their effect, preferably NO synthase inhibitors, particularly preferably nitro arginine, based on the total composition of the preparations.

It is particularly advantageous according to the invention verwen the invention Deten substances or cosmetic or topical dermatological preparations an effective content of substances used according to the invention for cosmeti or dermatological treatment or prophylaxis of unwanted skin conditions to use.

According to the invention, preparations containing the substances according to the invention contain, usual antioxidants are used.

Advantageously, the antioxidants are selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urotroic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and its derivatives (eg anserine), carotenoids, carotenes (eg α-carotene, β-carotene, lycopene) and their derivatives, aurothioglucose, propylthiouracil and other thiols (e.g. Thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, Cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thio dipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (eg buthionine sulfoximines, homocysteine sulfoximine, buthionine sulfones, penta, Hexa-, Heptathioninsulfoximin) in very low tolerated dosages (eg B. pmol to μmol / kg), further (metal) chelators (z. Α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (eg citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (for example γ-linolenic acid, linoleic acid, oleic acid), folic acid and derivatives thereof, alanine diacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (eg ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (eg., Vitamin E acetate), and Koniferylbenzoat of Benzoëharzes, rutinic acid and its derivatives, Feru lasäure and their derivatives, butylhydroxytoluene, Butylhydroxyanisol, Nordihydroguajak resin acid, Nordihydroguajaretsäure, Trihydroxybutyrophenon, uric acid and their derivatives, mannose and their derivatives Derivatives, zinc and its derivatives (eg ZnO, ZnSO ₄ ) selenium and its derivatives (eg selenium methionine), stilbenes and their derivatives (eg stilbene oxide, trans-Sti Ibenoxid) and the inventively suitable derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these drugs.

The amount of antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30 wt .-%, particularly preferably 0.05-20 wt .-%, ins particular 1-10 wt .-%, based on the total weight of the preparation.

The prophylaxis or the cosmetic or dermatological treatment with the inventions used according to the active ingredient or with the cosmetic or topical derma use tological preparations with an effective content of the invention active ingredient is carried out in the usual way, in such a way that the fiction used according to the active ingredient or the cosmetic or topical dermatological Preparations with an effective content of active ingredient used in the invention is applied to the affected skin areas.

Advantageously, the active ingredient used in the invention can be incorporated in üb Liche cosmetic and dermatological preparations, which come in various forms may be present. So they can z. As a solution, a water-in-oil type emulsion (W / O) or oil-in-water (O / W) type, or a multiple emulsion, for example water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O) type, a Hy drodispersion or lipodispersion, a gel, a solid stick or even an aerosol put.  

According to the invention emulsions, z. B. in the form of a Cream, a lotion, a cosmetic milk are advantageous and contain z. Fats, Oils, waxes and / or other fatty substances, as well as water and one or more emul gators, as commonly used for such a type of formulation the.

It is also possible and advantageous for the purposes of the present invention, the invention according to used active ingredient in aqueous systems or surfactant preparations for cleaning insertion of the skin and hair.

Of course, it is known to those skilled in the art that sophisticated cosmetic compositions usually not without the usual auxiliaries and additives are conceivable. He cosmetic preparations according to the invention can therefore cosmetic adjuvants contain, as they are commonly used in such preparations, for. B. Kon preservatives, bactericides, deodorizing substances, antiperspirants, Insect repellents, vitamins, antifoaming agents, dyes, Pig dyeing, thickening, softening, moisturizing tende and / or moisturizing substances, fats, oils, waxes or other common Be components of a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.

Mutatis mutandis, corresponding requirements apply to the formulation medical shear preparations.

Medical topical compositions according to the present invention ent usually keep one or more drugs in effective concentration. The For the sake of simplicity, a clear distinction between cosmetic and medi application and corresponding products to the legal requirements referred to in the Federal Republic of Germany (eg Cosmetics Regulation, Foodstuffs and drug law).

Cosmetic and dermatological preparations according to the invention also advantageously contain inorganic pigments based on metal oxides and / or other sparingly soluble or insoluble metal compounds, in particular the oxides of titanium (TiO ₂ ), zinc (ZnO), iron (eg Fe ₂ O) ₃ ), zirconium (ZrO ₂ ), silicon (SiO ₂ ), manganese (eg MnO), aluminum (Al ₂ O ₃ ), cerium (eg Ce ₂ O ₃ ), mixed oxides of the corresponding metals and Blends of such oxides. Particular preference is given to pigments based on TiO ₂ .

It is particularly advantageous in the context of the present invention, although not zwin when the inorganic pigments are in hydrophobic form, d. h. that she are superficially treated water-repellent. This surface treatment can consist in that the pigments according to known methods with a thin be provided hydrophobic layer.

One such method is, for example, that the hydrophobic surface layer after a reaction according to
n TiO ₂ + m (RO) ₃ Si-R '→ n TiO ₂ (surface)
is produced. n and m are to be used at will stoichiometric para meter, R and R 'are the desired organic radicals. For example, in analogy to DE-OS 33 14 742 illustrated hydrophobized pigments are advantageous.

Advantageous TiO ₂ pigments are available, for example, under the trade names MT 100 T from TAYCA, furthermore M 160 from Kemira and T 805 from Degussa.

Preparations according to the invention can, especially if crystalline or microcrystalline Solid, for example, inorganic micropigments in the inventive Zu preparations are to be incorporated, also anionic, nonionic and / or contain amphoteric surfactants. Surfactants are amphiphilic substances that are organic, nonpolar Solve substances in water.

The hydrophilic moieties of a surfactant molecule are mostly polar radio tional groups, for example -COO ^-, -OSO ₃ ^2-, -SO ₃ ^-, while the hydrophobic moieties are usually nonpolar hydrocarbon radicals. Surfactants are generally classified according to the nature and charge of the hydrophilic part of the molecule. Here four groups can be distinguished:

• - anionic surfactants,
• - cationic surfactants,
• Amphoteric surfactants and
• - nonionic surfactants.

Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In aqueous solution they form negatively charged organic ions in an acidic or neutral medium. Cationic surfactants are almost exclusively characterized by the presence of a quaternary ammonium group. In aqueous solution they form positively charged organic ions in the acidic or neutral medium. Amphoteric surfactants contain both anionic and cationic groups and behave accordingly in aqueous solution depending on the pH as anionic or cationic African surfactants. In a strongly acidic environment they have a positive charge and in alkaline Mi have a negative charge. In the neutral pH range, however, they are zwitterionic, as the following example is intended to illustrate:
RNH ₂ ⁺ CH ₂ CH ₂ COOH X ^- (at pH = 2): X ^- = any anion, e.g. B. Cl ^-
RNH ₂ ⁺ CH ₂ CH ₂ COO ^- (at pH = 7)
RNHCH ₂ CH ₂ COO ^- B ⁺ (at pH = 12): B ⁺ = any cation, e.g. Na ⁺

Typical of non-ionic surfactants are polyether chains. Form nonionic surfactants no ions in aqueous medium.

A. Anionic surfactants

Advantageously used anionic surfactants are acylamino acids (and their salts), such as

• 1. acylglutamates, for example sodium acylglutamate, di-TEA-palmitoylaspartate and Sodium Caprylic / Capric Glutamate,
• 2. Acyl peptides, for example palmitoyl-hydrolyzed milk protein, sodium cocoyl hydrolyzed soy protein and sodium / potassium cocoyl hydrolyzed collagen,
• 3. sarcosinates, for example myristoyl sarcosine, TEA lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate,
• 4. taurates, for example sodium lauroyl taurate and sodium methyl cocoyl taurate,  
• 5. Acyl lactates, lauroyl lactylate, caproyl lactylate
• 6. alaninates

Carboxylic acids and derivatives, such as

• 1. Carboxylic acids, for example lauric acid, aluminum stearate, magnesium alkoxide and zinc undecylenate,
• 2. Ester carboxylic acids, for example, calcium stearoyl lactylate, laureth-6 citrate and Sodium PEG-4 lauramide carboxylate,
• 3. Ether carboxylic acids, for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate,

Phosphoric acid esters and salts such as DEA-oleth-10-phosphate and Dilaureth-4 phosphate,
Sulfonic acids and salts, such as

• 1. Acyl-isethionates, z. B. sodium / ammonium cocoyl isethionate,
• 2. alkylarylsulfonates,
• 3. alkyl sulfonates, for example sodium coconut monoglyceride sulfate, sodium C _12-14 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,
• 4. Sulfosuccinates, for example dioctylsodium sulfosuccinate, disodium laurethsulfo succinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfo succinate

such as
Sulfuric acid esters, such as

• 1. alkyl ether sulfate, for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C _12-13 pareth sulfate,
• 2. Alkyl sulfates, for example sodium, ammonium and TEA lauryl sulfate.

B. Cationic surfactants

Advantageously to use cationic surfactants

• 1. alkylamines,
• 2. Alkylimidazoles,
• 3. Ethoxylated amines and
• 4. Quaternary surfactants
• 5. esterquats

Quaternary surfactants contain at least one N-atom containing 4 alkyl or aryl groups covalently linked. This results in a positive charge regardless of the pH. Advantageous are alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfine. The cationic surfactants used according to the invention may furthermore preferably be ge are selected from the group of quaternary ammonium compounds, in particular Benzyltrialkylammoniumchloride or bromides, such as Benzyldimethylstea rylammonium chloride, further Alkyltrialkylammoniumsalze, for example Cetyltrimethylammonium chloride or bromide, alkyldimethylhydroxyethylammonium chlorides or bromides, dialkyldimethylammonium chlorides or bromides, alkylamidoethyl trimethyl ammonium ether sulfates, alkyl pyridinium salts, for example lauryl or cetyl pyrimidinium chloride, imidazoline derivatives and compounds of cationic character such as amine oxides, for example alkyldimethylamine oxides or alkylaminoethyldimethyl amine oxides. Cetyltrimethylammonium salts are particularly advantageous to use.

C. Amphoteric surfactants

Advantageously used amphoteric surfactants

• 1. acyl / dialkylethylenediamine, for example, sodium acylamphoacetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, sodium acyl amphohydroxypropyl sulfonate, disodium acylamphodiacetate and sodium acylamphopropionate,
• 2. N-alkylamino acids, for example aminopropylalkylglutamide, alkylaminopropion acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.

D. Nonionic surfactants

Advantageously used nonionic surfactants are

• 1. Alcohols,
• 2. alkanolamides, such as cocamide MEA / DEA / MIPA,
• 3. amine oxides, such as cocoamidopropylamine oxide,
• 4. Esters obtained by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
• 5. Ethers, for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated choles steric, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated La noline, ethoxylated / propoxylated polysiloxanes, propoxylated POE ethers and alkyl polyglycosides such as lauryl glucoside, decyl glycoside and cocoglycoside.
• 6. sucrose ester, ether  
• 7. Polyglycerol esters, diglycerol esters, monoglycerol esters
• 8. Methyl glucose esters, esters of hydroxy acids

It is also advantageous to use a combination of anionic and / or amphoteric surfactants with one or more nonionic surfactants.

The surface-active substance can be used in a concentration between 1 and 95% by weight. present in the preparations according to the invention, based on the total weight the preparations.

The lipid phase of the cosmetic or dermatological emulsions according to the invention can advantageously be selected from the following substance group:

• - mineral oils, mineral waxes
• - Oils such as triglycerides of capric or caprylic acid, also natural oils such as z. Castor oil;
• - Fats, waxes and other natural and synthetic fats, preferably Esters of fatty acids with lower C-number alcohols, e.g. B. with isopropanol, propy glycol or glycerol, or esters of fatty alcohols with lower alkanoic acids C number or with fatty acids;
• - alkyl benzoate;
• - Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes so like hybrids of it.

The oil phase of the emulsions of the present invention is advantageously selected from Group of esters of saturated and / or unsaturated, branched and / or unreacted branched alkanecarboxylic acids of a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms. Such ester oils can then be advantageous ge are selected from the group isopropyl myristate, isopropyl palmitate, isopropyl stearate, iso propyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, Isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-Oc tyldodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate and synthetic, semi-synthetic and natural mixtures of such esters, e.g. B. jojoba oil.  

Furthermore, the oil phase can be advantageously selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the Group of saturated or unsaturated, branched or unbranched alcohols, and the fatty acid triglycerides, namely the triglycerol esters of saturated and / or un saturated, branched and / or unbranched alkanecarboxylic acids of a chain length from 8 to 24, in particular 12-18 C atoms. The fatty acid triglycerides may be included For example, be advantageously selected from the group of synthetic, semisyntheti and natural oils, eg. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, Almond oil, palm oil, coconut oil, palm kernel oil, and the like.

Any mixtures of such oil and wax components are advantageous in the Use of the present invention. It may also be advantageous if necessary waxes, for example cetyl palmitate, as the sole lipid component of the oil phase use.

Advantageously, the oil phase is selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C _12-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.

Particularly advantageous are mixtures of C _12-15 alkyl benzoate and 2-Ethylhexylisostea rat, mixtures of C _12-15 alkyl benzoate and Isotridecylisononanoat and mixtures of C _12-15 alkyl benzoate, 2-Ethylhexylisostearat and Isotridecylisononanoat.

Of the hydrocarbons, paraffin oil, squalane and squalene are advantageous in the sense to use the present invention.

Advantageously, the oil phase may further comprise a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other Ölpha senkomponenten except the silicone oil or silicone oils. Such silicones or silicone oils may be present as monomers, which are typically characterized by structural elements, as follows:

As present invention advantageously used linear silicones with multiple siloxyl units are characterized in general by structural elements as follows:

wherein the silicon atoms can be substituted with identical or different alkyl radicals and / or aryl radicals, which are here generalized by the radicals R ₁ -R ₄ (to say that the number of different radicals is not necessarily limited to 4). m can assume values of 2 to 200,000.

Cyclic silicones which are advantageously used in accordance with the invention are generally characterized by structural elements as follows:

wherein the silicon atoms can be substituted with identical or different alkyl radicals and / or aryl radicals, which are here generalized by the radicals R ₁ -R ₄ (to say that the number of different radicals is not necessarily limited to 4). n can assume values of 3/2 to 20. Broken values for n take into account that odd numbers of siloxyl groups may be present in the cycle.

Advantageously, cyclomethicone (eg decamethylcyclopentasiloxane) is considered to be inventive used to be used silicone oil. But other silicone oils are also beneficial For purposes of the present invention, for example Undecamethylcyclotrisi  loxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyl dimethicone, behenoxydi methicone.

Also advantageous are mixtures of cyclomethicone and Isotridecylisononanoat, and those from cyclomethicone and 2-ethylhexyl isostearate.

But it is also advantageous silicone oils similar constitution as the above Neten to select compounds whose derivatized organic side chains, for example are polyethoxylated and / or polypropoxylated. These include, for example, poly siloxane polyalkyl polyether copolymers, such as the cetyl dimethicone copolyol, which is (cetyl) Dimethicone copolyol (and) polyglyceryl-4-isostearate (and) hexyl laurate).

Also particularly advantageous are mixtures of cyclomethicone and isotridecylisono nanoate, from cyclomethicone and 2-ethylhexyl isostearate.

The aqueous phase of the preparations according to the invention optionally contains partly alcohols, diols or polyols low C number, and their ethers, preferably Ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, di ethylene glycol monomethyl or monoethyl ether and analogous products, furthermore alcohols low C number, z. As ethanol, isopropanol, 1,2-propanediol, glycerol and in particular one or more thickening agents, which or which are advantageously chosen can be selected from the group silicon dioxide, aluminum silicates.

Preparations according to the invention present as emulsions contain in particular advantageously one or more hydrocolloids. These hydrocolloids can ge advantageous are selected from the group of gums, polysaccharides, cellulose derivatives, layer silicates, polyacrylates and / or other polymers.

Preparations according to the invention present as hydrogels contain one or more more hydrocolloids. These hydrocolloids may be advantageous from the aforementioned group to get voted.

The gums include plant or tree juices that harden in the air and har ze form or extracts from aquatic plants. From this group can be beneficial in  For the purposes of the present invention, for example, gum arabic, Jo hanis bread flour, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, Agar, Algine, Chondrus, Xanthan gum.

Also advantageous is the use of derivatized gums such. B. hydroxy propyl guar (Jaguar® HP 8).

Among the polysaccharides and derivatives are z. Hyaluronic acid, chitin and Chitosan, chondroitin sulphates, starch and starch derivatives.

Among the cellulose derivatives are z. Methylcellulose, carboxymethylcellulose, Hydroxyethylcellulose, hydroxypropylmethylcellulose.

Among the phyllosilicates are naturally occurring and synthetic clay earths such as As montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates like Veegum®. These can be used as such or in modified form as z. Stearylalkonium hectorites.

Furthermore, it is also advantageous to use silica gels.

Among the polyacrylates are z. Carbopol types from Goodrich (Carbo pol 980, 981, 1382, 5984, 2984, EDT 2001 or Pemulen TR2).

Among the polymers are z. As polyacrylamides (Seppigel 305), polyvinyl alcohol hole, PVP, PVP / VA copolymers, polyglycols.

Preparations according to the invention present as emulsions contain one or several emulsifiers. These emulsifiers can be chosen advantageously from the Group of nonionic, anionic, cationic or amphoteric emulsifiers.

Among the nonionic emulsifiers are

• a) partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxy derivatives (eg glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, Sucrosestearate)
• b) ethoxylated fatty alcohols and fatty acids  
• c) ethoxylated fatty amines, fatty acid amides, fatty acid alkanolamides
• d) alkylphenol polyglycol ethers (eg Triton X)

Among the anionic emulsifiers are

• a) soaps (eg sodium stearate)
• b) fatty alcohol sulfates
• c) mono-, di- and Trialkylphosphosäureester and their ethoxylates

Among the cationic emulsifiers are

• a) quaternary ammonium compounds with a long-chain aliphatic radical z. B. Distearyldimonium chlorides

Among the amphoteric emulsifiers are

• a) Alkylamininoalkancarbonsäuren
• b) betaines, sulfobetaines
• c) imidazoline

There are also naturally occurring emulsifiers, including beeswax, wool wax, lecithin and sterols.

For example, O / W emulsifiers can be advantageously selected from the group of polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, eg. B .:

• - the fatty alcohol ethoxylates
• - the ethoxylated wool wax alcohols,
• - The polyethylene glycol ether of the general formula
  RO - (- CH ₂ -CH ₂ -O-) _n -R ',
• - The fatty acid ethoxylates of the general formula
  R-COO - (- CH ₂ -CH ₂ -O-) _n -H,
• - The etherified fatty acid ethoxylates of the general formula
  R-COO - (- CH ₂ -CH ₂ -O-) _n -R ',
• - The esterified fatty acid ethoxylates of the general formula
  R-COO - (- CH ₂ -CH ₂ -O-) _n -C (O) -R ',
• - The Polyethylenglycolglycerinfettsäureester
• - the ethoxylated sorbitan ester
• - the cholesterol ethoxylates  
• - the ethoxylated triglycerides
• - The alkyl ether carboxylic acids of the general formula
  RO - (- CH ₂ -CH ₂ -O-) _n -CN ₂ -COOH nd n represent a number from 5 to 30,
• The polyoxyethylene sorbitol fatty acid ester,
• - The alkyl ether sulfates of the general formula
  RO - (- CH ₂ -CH ₂ -O-) _n -SO ₃ -H
• - The fatty alcohol propoxylates of the general formula
  RO - (- CH ₂ -CH (CH ₃ ) -O-) _n -H,
• - The polypropylene glycol ether of the general formula
  RO - (- CH ₂ -CH (CH ₃ ) -O-) _n -R ',
• The propoxylated wool wax alcohols,
• - the etherified fatty acid propoxylates
  R-COO - (- CH ₂ -CH (CH ₃ ) -O-) _n -R ',
• - The esterified fatty acid propoxylates of the general formula
  R-COO - (- CH ₂ -CH (CH ₃ ) -O-) _n -C (O) -R ',
• - The fatty acid propoxylates of the general formula
  R-COO - (- CH ₂ -CH (CH ₃ ) -O-) _n -H,
• The polypropylene glycol glycerin fatty acid ester
• - the propoxylated sorbitan ester
• - the cholesterol propoxylates
• - the propoxylated triglycerides
• - The alkyl ether carboxylic acids of the general formula
  RO - (- CH ₂ -CH (CH ₃ ) O-) _n -CH ₂ -COOH
• - The alkyl ether sulfates or these sulfates underlying acids of all general formula
  RO - (- CH ₂ -CH (CH ₃₎ -O-) _n -SO ₃ -H
• the fatty alcohol ethoxylates / propoxylates of the general formula
  ROX _n -Y _m -H,
• - The polypropylene glycol ether of the general formula
  ROX _n -Y _m -R ',
• - The etherified fatty acid propoxylates of the general formula
  R-COO-X _n -Y _m -R ',
• - The fatty acid ethoxylates / propoxylates of the general formula
  R-COO-X _n -Y _m -H.

According to the invention, the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers ge  selects from the group of substances with HLB values of 11-18, especially Partly with HLB values of 14.5-15.5, provided the O / W emulsifiers saturated Radicals R and R 'have. Do the O / W emulsifiers unsaturated radicals R and / or R 'on, or are Isoalkylderivate, the preferred HLB value of such Emul gators also lower or higher.

It is advantageous to choose the fatty alcohol ethoxylates from the group of ethoxylated Stearylal alcohols, cetyl alcohols, Cetylstearylalkohole (Cetearylalkohole). Particularly preferred are:
Polyethylene glycol (13) stearyl ether (steareth-13), polyethylene glycol (14) stearyl ether (Stea reth-14), polyethylene glycol (15) stearyl ether (steareth-15), polyethylene glycol (16) stearyl ether (steareth-16), polyethylene glycol (17) stearyl ether (steareth-17), polyethylene glycol (18) stearyl ether (steareth-18), polyethylene glycol (19) stearyl ether (steareth-19), polyethylene glycol (20) stearyl ether (steareth-20),
Polyethylene glycol (12) isostearyl ether (isosteareth-12), polyethylene glycol (13) isostearyl ether (isosteareth-13), polyethylene glycol (14) isostearyl ether (isosteareth-14), polyethylene glycol (15) isostearyl ether (isosteareth-15), polyethylene glycol (16) isostearyl ether (Isostea reth-16), polyethylene glycol (17) isostearyl ether (isosteareth-17), polyethylene glycol (18) isostearyl ether (isosteareth-18), polyethylene glycol (19) isostearyl ether (isosteareth-19), polyethylene glycol (20) isostearyl ether (isosteareth-20) )
Polyethylene glycol (13) Cetyl ether (Ceteth-13), Polyethylene glycol (14) Cetyl ether (Ceteth-14), Polyethylene glycol (15) Cetyl ether (Ceteth-15), Polyethylene glycol (16) Cetyl ether (Ceteth-16), Polyethylene glycol (17) Cetyl ether ( Ceteth-17), polyethylene glycol (18) cetyl ether (ceteth-18), polyethylene glycol (19) cetyl ether (ceteth-19), polyethylene glycol (20) cetyl ether (ceteth-20),
Polyethylene glycol (13) isocetyl ether (isoceteth-13), polyethylene glycol (14) isocetyl ether (isoceteth-14), polyethylene glycol (15) isocetyl ether (isoceteth-15), polyethylene glycol (16) iso cetyl ether (isoceteth-16), polyethylene glycol (17) isocetyl ether (isoceteth-17), polyethylene glycol (18) isocetyl ether (isoceteth-18), polyethylene glycol (19) isocetyl ether (isoceteth-19), polyethylene glycol (20) isocetyl ether (isoceteth-20),
Polyethylene glycol (12) oleyl ether (Oleth-12), polyethylene glycol (13) oleyl ether (Oleth-13), polyethylene glycol (14) oleyl ether (Oleth-14), polyethylene glycol (15) oleyl ether (Oleth-15),
Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isolau reth-12),
Polyethylene glycol (13) cetyl stearyl ether (ceteareth-13), polyethylene glycol (14) cetyl stearyl ether (ceteareth-14), polyethylene glycol (15) cetyl stearyl ether (ceteareth-15), polyethylene glycol (16) cetyl stearyl ether (ceteareth-16), polyethylene glycol (17) cetyl stearyl ether (Cetea reth-17), polyethylene glycol (18) cetyl stearyl ether (ceteareth-18), polyethylene glycol (19) cetyl stearyl ether (ceteareth-19), polyethylene glycol (20) cetyl stearyl ether (ceteareth-20).

It is also advantageous to choose the fatty acid ethoxylates from the following group:
Polyethylene glycol (20) stearate, polyethylene glycol (21) stearate, polyethylene glycol (22) stearate, polyethylene glycol (23) stearate, polyethylene glycol (24) stearate, polyethylene glycol (25) stearate,
Polyethylene glycol (12) isostearate, polyethylene glycol (13) isostearate, polyethylene glycol (14) isostearate, polyethylene glycol (15) isostearate, polyethylene glycol (16) isostearate, polyethylene glycol (17) isostearate, polyethylene glycol (18) isostearate, polyethylene glycol (19) isostearate, polyethylene glycol (20) isostearate, polyethylene glycol (21) isostearate, polyethylene glycol (22) isostearate, polyethylene glycol (23) isostearate, polyethylene glycol (24) isostearate, polyethylene glycol (25) isostearate,
Polyethylene glycol (12) oleate, polyethylene glycol (13) oleate, polyethylene glycol (14) oleate, polyethylene glycol (15) oleate, polyethylene glycol (16) oleate, polyethylene glycol (17) oleate, polyethylene glycol (18) oleate, polyethylene glycol (19) oleate, polyethylene glycol (20) oleate.

The ethoxylated alkyl ether carboxylic acid or its salt may advantageously be sodium lime Reth-11-carboxylate can be used.

As the alkyl ether sulfate, sodium laureth 1-4 sulfate can be advantageously used.

As the ethoxylated cholesterol derivative, polyethylene glycol (30) may advantageously be cholesteryl ether can be used. Also polyethylene glycol (25) soybean oil has been proven.  

As ethoxylated triglycerides, the polyethylene glycol (60) Evening Prim rose glycerides are used (Evening Primrose = evening primrose).

Furthermore, it is advantageous, the Polyethylenglycolglycerinfettsäureester from the group Po lyethyleneglycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, Polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl caprate / caprinate, polyethylene glycol (20) glyceryl oleate, polyethylene glycol (20) glyceryl isostea advice to choose polyethylene glycol (18) glyceryl oleate / cocoate.

It is also convenient to use the sorbitan esters from the group of polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbi to choose tanmonooleat.

As advantageous W / O emulsifiers can be used: fatty alcohols with 8 to 30 Carbon atoms, monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular re 12-18 C-atoms, diglycerol esters saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12-18 C atoms, monoglycerol ethers saturated and / or unsaturated, ver branched and / or unbranched alcohols of a chain length of 8 to 24, in particular 12-18 C-atoms, diglycerol ethers saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12-18 C atoms and sorbitan esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12-18 C-atoms.

Particularly advantageous W / O emulsifiers are glyceryl monostearate, glyceryl monoiso stearate, glyceryl monomyristate, glyceryl monooleate, diglyceryl monostearate, diglyceryl monoisostearate, propylene glycol monostearate, propylene glycol monoisostearate, propylene glycol colmonocaprylate, propylene glycol monolaurate, sorbitan monoisostearate, sorbitan monolaur sorbitan monocaprylate, sorbitan monoisooleate, sucrose distearate, cetyl alcohol,  Stearyl alcohol, arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, Chimyl alcohol, polyethylene glycol (2) stearyl ether (steareth-2), glyceryl monolaurate, glyce rylmonocaprinate, glyceryl monocaprylate.

Favorable are those cosmetic and dermatological preparations which are in the form a sunscreen. But it is also advantageous in the sense of the present the inventions, such cosmetic and dermatological preparations erstro len, whose main purpose is not protection against sunlight, but nevertheless contain a content of UV-protective substances. So z. B. ge in day creams usually UV-A or UV-B filter substances incorporated.

Also, UV protectants, as well as antioxidants and, if desired, Preservatives, effective protection of the preparations themselves against spoilage represents.

Accordingly, the preparations according to the present invention before preferably in addition to one or more UV filter substances according to the invention additional at least one further UV-A and / or UV-B filter substance. The formulations may, although not necessary, optionally also one or more organic and / or inorganic pigments as UV filter substances, which in the What Ser- and / or the oil phase can be present.

Preferred inorganic pigments are metal oxides and / or other water-insoluble or insoluble metal compounds, in particular oxides of titanium (TiO ₂ ), zinc (ZnO), iron (eg Fe ₂ O ₃ ), zirconium (ZrO ₂ ), silicon (SiO ₂ ), manganese (for example MnO), aluminum (Al ₂ O ₃ ), cerium (for example Ce ₂ O ₃ ), mixed oxides of the corresponding metals and mixtures of such oxides.

Such pigments may advantageously be superficial in the sense of the present invention be treated ("coated"), wherein, for example, an amphiphilic or hydrophobic Cha be formed or should remain preserved character. This surface treatment can consist in that the pigments according to known methods with a thin be provided hydrophobic layer.  

According to the invention are advantageous z. As titanium dioxide pigments which are coated with octylsilanol be. Suitable titanium dioxide particles are available under the trade name T805 from Degussa. Also particularly advantageous are aluminum stearate coated with TiO ₂ pigments, z. As those available under the trade name MT 100 T from TAYCA.

Another advantageous coating of the inorganic pigments consists of dimethyl polysiloxane (also: dimethicone), a mixture of fully methylated, linear siloxane poly monomers which are terminally blocked with trimethylsiloxy units. Especially advantageous For the purposes of the present invention are zinc oxide pigments, be in this way be be layered.

Furthermore, a coating of the inorganic pigments with a mixture is advantageous of dimethylpolysiloxane, in particular dimethylpolysiloxane with an average Chain length of 200 to 350 dimethylsiloxane units, and silica gel, which is also known as Simethicone is called. It is particularly advantageous if the inorganic Pigments additionally with aluminum hydroxide or alumina hydrate (also: alumina, CAS No .: 1333-84-2). Titanium dioxides which are particularly advantageous are Simethicone and alumina are coated, wherein the coating also contains water can. An example of this is that under the trade name Eusolex T2000 at the Company Merck available titanium dioxide.

Advantageous organic pigment in the context of the present invention is 2,2'-methyl-bis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol) [ INCI: bisoctyl triazole], which is represented by the chemical structural formula

and sold under the trade name Tinosorb® M by CIBA-Che mikalia GmbH is available.

Advantageously, preparations according to the invention contain substances which absorb UV radiation in the Absorb UV-A and / or UV-B range, the total amount of Filterubstan zen z. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0% by weight, based on the total weight of the preparations, of kos to provide metic preparations which protect the hair or the skin from the protect entire area of ultraviolet radiation. They can also be called suns protect the hair or skin.

Advantageous UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS no. 70356-09-1), which was sold by Givaudan under the trademark Parsol® 1789 and Merck under the trade name Eusolex® 9020 is sold.

Further advantageous UV-A filter substances are the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid

and their salts, especially the corresponding sodium, potassium or Triethanolammo nium salts, in particular the phenylene-4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt

with the INCI name Bisimidazylate, which, for example under the Handelsbe Neo Heliopan AP is available from Haarmann & Reimer.  

Also advantageous are the 1,4-di (2-oxo-10-sulfo-3-bomylidenemethyl) benzene and its salts (especially the corresponding 10-sulfato compounds, in particular the ent speaking sodium, potassium or triethanolammonium salt ), which is also referred to as benzene-1,4-di (2-oxo-3-bomylidenemethyl-10-sulfonic acid) and is characterized by the following structure:

Advantageous UV filter substances in the context of the present invention are also soge called broadband filter, d. H. Filter substances containing both UV-A and UV-B radiation absorb.

Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinolinyltriazine derivatives having the following structure:

wherein R ¹ , R ² and R ^{3 are} independently selected from the group of ver branched and unbranched alkyl groups having 1 to 10 carbon atoms or represent a single hydrogen atom. Particularly preferred are 2,4-bis - {(4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI: Aniso Tria zin) available under the tradename Tinosorb® S from CIBA-Chemikalien GmbH and 4,4 ', (4,4 "- (1,3,5-triazine-2,4,6-triyltriimino) tris-benzoic acid tris (2-ethylhexyl ester), synonym: 2,4,6-tris [anilino (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCI: Octyl Triazone) , which is marketed by BASF Aktiengesellschaft under the trade name UVINUL® T 150.

Other UV filter substances, which are the structural motif

are advantageous UV filter substances in the context of the present invention, for example, those described in European Published Patent Application EP 570 838 A1 nen s-triazine derivatives, their chemical structure by the generic formula

is reproduced, wherein
R is a branched or unbranched C ₁ -C ₁₈ -alkyl radical, a C ₅ -C ₁₂ -cycloalkyl radical, optionally substituted by one or more C ₁ -C ₄ -alkyl groups,
X represents an oxygen atom or an NH group,
R _{1 is} a branched or unbranched C ₁ -C ₁₈ -alkyl radical, a C ₅ -C ₁₂ -cycloalkyl radical, optionally substituted by one or more C ₁ -C ₄ -alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group the formula

means in which
A is a branched or unbranched C ₁ -C ₁₈ -alkyl radical, a C ₅ -C ₁₂ -cycloalkyl or aryl radical, optionally substituted by one or more C ₁ -C ₄ -alkyl groups,
R _{3 represents} a hydrogen atom or a methyl group,
n represents a number from 1 to 10,
R _{2 is} a branched or unbranched C ₁ -C ₁₈ -alkyl radical, a C ₅ -C ₁₂ -cycloalkyl radical, optionally substituted by one or more C ₁ -C ₄ -alkyl groups,
when X represents the NH group, and
a branched or unbranched C ₁ -C ₁₈ -alkyl radical, a C ₅ -C ₁₂ -cycloalkyl radical, optionally substituted by one or more C ₁ -C ₄ -alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula

means in which
A is a branched or unbranched C ₁ -C ₁₈ -alkyl radical, a C ₅ -C ₁₂ -cycloalkyl or aryl radical, optionally substituted by one or more C ₁ -C ₄ -alkyl groups,
R _{3 represents} a hydrogen atom or a methyl group,
n represents a number from 1 to 10,
when X represents an oxygen atom.

Particularly preferred UV filter substance in the context of the present invention is also an unsymmetrically substituted s-triazine whose chemical structure is represented by the formula

which is also referred to below as dioctylbutylamidotriazone (INCI: Dioctylbutamidotriazone) and under the trade name UVASORB HEB is available from Sigma 3V.

Also in the European Patent Application 775,698 preferred bis-Resorcinyltriazinderivate be described whose chemical structure by generi cal formula

is reproduced, wherein R ₁ , R ₂ and A _{1 represent a} wide variety of organic radicals animals.

Advantageous in the context of the present invention are also the 2,4-bis - {[4- (3-sulfonato) - 2-hydroxy-propyloxy) -2-hydroxy-phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine sodium salt, the 2,4-bis - {[4- (3- (2-propyloxy) -2-hydroxy-propyloxy) -2-hydroxy] -phenyl} -6- (4-methoxy phenyl) -1,3,5-triazine which is 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy) -phenyl} -6- [4- (2-meth oxyethyl-carboxyl) -phenylamino) -1,3,5-triazine which is 2,4-bis - {[4- (3- (2-propyloxy) -2-hydroxy  propyloxy) -2-hydroxy] -phenyl) -6- [4- (2-ethylcarboxyl) -phenylamino] -1,3,5-triazine, the 2,4- Bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (1-methylpyrrol-2-yl) -1,3,5-triazine das 2,4-bis - {[4-tris (trimethylsiloxy-silylpropyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) - 1,3,5-triazine which is 2,4-bis - {[4- (2 "-methylpropenyloxy) -2-hydroxy] -phenyl} -6- (4-methoxy phenyl) -1,3,5-triazine and the 2,4-bis - {[4- (1 ', 1', 1 ', 3', 5 ', 5', 5'-heptamethylsiloxy-2 "-methyl propyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine.

An advantageous broadband filter for the purposes of the present invention is the 2,2'-methyl-len- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol), which by the chemical structural formula

and sold under the trade name Tinosorb® M by CIBA-Che mikalia GmbH is available.

Advantageous broadband filter according to the present invention is further the 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] di siloxanyl] propyl] phenol (CAS No .: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is represented by the chemical structural formula

is marked.  

The UV-B filters may be oil-soluble or water-soluble. Advantageous oil-soluble UV-B filter substances are z. B .:
3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
4-aminobenzoic acid derivatives, preferably (2- ethylhexyl) 4- (dimethylamino) benzoate, 4- (dimethylamino) benzoic acid amyl ester;
2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine;
Esters of benzalmalonic acid, preferably di (2-ethylhexyl) 4-methoxybenzalmalonate;
Esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone and UV-bound to polymers.

Advantageous water-soluble UV-B filter substances are z. B .:
Salts of 2-phenylbenzimidazole-5-sulfonic acid, such as its sodium, potassium or its Trietha nolammonium salt, and the sulfonic acid itself;
Sulfonic acid derivatives of 3-Benzylidencamphers, such as. B. 4- (2-oxo-3-bornylidenme methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidenemethyl) sulfonic acid and salts thereof.

Another light stabilizer filter substance which can advantageously be used in accordance with the invention is ethylhexyl 2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul® N 539 and has the following structure:

It can also be of considerable advantage, polymer-bound or polymeric UV filters to use substances in preparations according to the present invention, esp especially those as described in WO-A-92/20690.

Furthermore, it may be advantageous, according to the invention, to obtain further UVA and / or to incorporate UV-B filters into cosmetic or dermatological preparations, for example, certain salicylic acid derivatives such as 4-isopropylbenzyl salicylate, 2-ethyl hexyl salicylate (= octyl salicylate), homomenthyl salicylate.

The list of said UV filters used in the context of the present invention of course, should not be limiting.

The following examples are intended to illustrate but not limit the invention. The Numbers are by weight, unless otherwise specified.  

example 1 O / W cream

Wt .-% glyceryl stearate 4.00 PEG-40 Stearate 1.00 cetyl alcohol 3.00 Caprylic / capric 5.00 mineral oil 5.00 nitroguanidine 0.10 tocopherol 0.10 Trisodium EDTA 0.10 preservative q.s. Carbomer 3.00 Sodium hydroxide 45% q.s. glycerin 5.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 2 O / W cream

Wt .-% Glycerylate SE 3.00 stearic acid 1.00 cetyl alcohol 2.00 Caprylic / capric 3.00 dicaprylyl 4.00 mineral oil 2.00 7-nitroindole 0.50 preservative q.s. Carbomer 0.10 Sodium hydroxide 45% q.s. glycerin 3.00 Butyleneglycol 3.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 3 O / W cream

Wt .-% glyceryl stearate 2.00 Stearylalcohol 5.00 Caprylic / capric 4.00 octyldodecanol 2.00 TiO ₂ 1.00 4-methylbenzylidenecamphor 1.00 Butylmethoxydibenzolymethan 0.50 S-methylthiourea 0.20 biotin 0.05 Trisodium EDTA 0.10 preservative q.s. Sodium hydroxide 45% q.s. glycerin 4.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 4 O / W cream

Wt .-% Polyglyceryl-3-methylglucose distearate 3.00 cetyl alcohol 3.00 Caprylic / capric 3.00 dicaprylyl 2.00 mineral oil 3.00 iminopiperidine 0.10 Trisodium EDTA 0.10 preservative q.s. Carbomer 0.10 Sodium hydroxide 45% q.s. glycerin 3, 00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 5 O / W cream

Wt .-% glyceryl stearate 2.00 sorbitan 2.00 Cetylstearylalcohol 2.00 Caprylic / capric 3.00 octyldodecanol 2.00 dicaprylyl 1.00 Aminoguanidine hemisulphate 0.10 tocopherol 0.20 preservative q.s. Carbomer 0.10 Sodium hydroxide 45% q.s. glycerin 3.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 6 O / W cream

Wt .-% Glycerylate SE 5.00 Stearylalcohol 2.00 Caprylic / capric 2.00 octyldodecanol 2.00 dimethicone 2.00 TiO ₂ 2.00 4-methylbenzylidenecamphor 1.00 Butylmethoxydibenzolymethan 0.50 nitroarginine 0.20 preservative q.s. Carbomer 0.15 Sodium hydroxide 45% q.s. glycerin 3.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 7 O / W cream

Wt .-% glyceryl stearate 2.00 Cetylstearylalcohol 3.00 C _12-15 alkyl benzoates 2.00 octyldodecanol 2.00 mineral oil 4.00 diphenyleneiodonium chloride 0.40 preservative q.s. Carbomer 0.10 Sodium hydroxide 45% q.s. Butyleneglycol 3.00 Alcohol Denat. 3.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 8 O / W cream

Wt .-% glyceryl stearate 2, 00 Cetylstearylalcohol 1.00 C _12-15 alkyl benzoates 3.00 mineral oil 2.00 diphenyleneiodonium chloride 0.40 Well ₃ HEDTA 0.20 preservative q.s. Xanthan gum 0.20 Sodium hydroxide 45% q.s. glycerin 3.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 9 O / W cream

Wt .-% stearic acid 2.50 cetyl alcohol 3.00 octyldodecanol 4.00 cyclomethicone 0.50 nitroguanidine 0.20 preservative q.s. Carbomer 0.05 Sodium hydroxide 45% q.s. glycerin 5.00 Alcohol Denat. 3.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 10 O / W cream

Wt .-% stearic acid 3.50 cetyl alcohol 4.50 Cetylstearylalcohol 0.50 octyldodecanol 6.00 cyclomethicone 2.00 4-methylbenzylidenecamphor 1.00 Butylmethoxydibenzolymethan 0.50 norharman 0.10 tocopherol 0.05 Trisodium EDTA 0.20 preservative q.s. Carbomer 0.05 Sodium hydroxide 45% q.s. glycerin 3.00 Perfume q. s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 11 W / O emulsion

Wt .-% Polyglyceryl-2 dipolyhydroxystearate 5.00 Anisotriazin 2.00 dioctyl 3.00 octocrylene 7.00 dioctyl 1.00 Bisimidazylat 1.00 Phenylbenzmidazolsulfonsäure 0.50 zinc oxide 3.00 dicaprylyl 10.00 dicaprylyl 5.00 cyclomethicone 2.00 PVP hexadecene copolymer 0.50 glycerin 3.00 _MgSO4 1.00 Vitamin E acetate 0.50 nitroguanidine 0.30 methylparaben 0.50 phenoxyethanol 0.50 ethanol 3.00 Perfume q. s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 12 W / O emulsion

Wt .-% cetyl dimethicone 2.50 ethylhexylmethoxycinnamate 8.00 Anisotriazin 2.50 dioctyl 1.00 4-methylbenzylidenecamphor 2.00 octocrylene 2.50 Bisimidazylat 2.00 Titanium dioxide 2.00 zinc oxide 1.00 dimethicone 4.00 cyclomethicone 25,00 octoxyglycerol 0.30 glycerin 7.50 Glycine soy 1.00 _MgSO4 0.50 Carboxy-PTIO potassium 0.10 DMDM hydantoin 0.60 phenoxyethanol 0.40 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 13 W / O emulsion

Wt .-% cetyl dimethicone 4.00 ethylhexylmethoxycinnamate 5.00 Anisotriazin 2.00 butylmethoxydibenzoylmethane 1.00 ethylhexyl triazone 4.00 4-methylbenzylidenecamphor 4.00 dioctyl 2.00 Phenylbenzmidazolsulfonsäure 3.00 zinc oxide 0.50 C _12-15 alkyl benzoates 9.00 Butyleneglycoldicaprylat / dicaprate 8.00 dimethicone 5.00 PVP hexadecene copolymer 0.50 glycerin 7.50 _MgSO4 0.50 L-NIL dihydrochloride 0.05 DMDM hydantoin 0.20 methylparaben 0.15 phenoxyethanol 1.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 14 W / O emulsion

Wt .-% Polyglyceryl-2 dipolyhydroxystearate 4.50 ethylhexylmethoxycinnamate 4.00 Anisotriazin 2.50 dioctyl 3.00 4-methylbenzylidenecamphor 2.00 octocrylene 2.50 Phenylbenzmidazolsulfonsäure 2.00 Titanium dioxide 3.00 mineral oil 8.00 dicaprylyl 7.00 Butyleneglycoldicaprylat / dicaprate 4.00 cyclomethicone 2.00 PVP hexadecene copolymer 1.00 octoxyglycerol 0.50 glycerin 2.50 MgCl ₂ 0.70 Vitamin E acetate 1.00 Aminoguanidine hemisulphate 0.20 phenoxyethanol 0.60 ethanol 1.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 15 W / O emulsion

Wt .-% Polyglyceryl-2 dipolyhydroxystearate 4.00 Wool alcohol 0.50 Isohexadecan 1.00 myristate 0.50 Cera Microcristallina + Paraffinum Liquidum 1.00 butylmethoxydibenzoylmethane 0.50 4-methylbenzylidenecamphor 1.00 Butyleneglycoldicaprylat / dicaprate 4.00 glycerin 5.00 Vitamin E acetate 0.50 iminopiperidine 0.05 S-methylisothiourea 0.10 Well ₃ HEDTA 0.20 methylparaben q.s. phenoxyethanol q.s. Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 16 W / O emulsion

Wt .-% Polyglyceryl-2 dipolyhydroxystearate 5.00 Wool alcohol 1.50 Isohexadecan 2.00 myristate 1.50 Cera Microcristallina + Paraffinum Liquidum 2.00 butylmethoxydibenzoylmethane 1.50 4-methylbenzylidenecamphor 3.00 Butyleneglycoldicaprylat / dicaprate 5.00 Shea butter 0.50 Butyleneglycol 6.00 octoxyglycerol 3.00 Vitamin E acetate 1.00 diphenyleneiodonium chloride 0.15 Well ₃ HEDTA 0.20 methylparaben q.s. phenoxyethanol q.s. ethanol 3.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 17 W / O emulsion

Wt .-% PEG-30 dipolyhydroxystearate 5.00 butylmethoxydibenzoylmethane 2.00 ethylhexyl triazone 3.00 octocrylene 4.00 Bisimidazylat 0.50 Titanium dioxide 1.50 zinc oxide 2.00 mineral oil 10.00 Butyleneglycoldicaprylat / dicaprate 2.00 dicaprylyl 6.00 dimethicone 1.00 Shea butter 3.00 octoxyglycerol 1.00 Glycine soy 1.50 MgCl ₂ 1.00 Vitamin E acetate 0.25 thiocarbamate 1.00 DMDM hydantoin 0.40 methylparaben 0.25 ethanol 1.50 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 18 Hydro dispersion

Wt .-% Polyoxyethylene (20) cetylstearyl ether 1.00 Acrylates / C10-30 Alkyl Acrylic Crosspolymer 0.50 butylmethoxydibenzoylmethane 1.00 ethylhexyl triazone 4.00 4-methylbenzylidenecamphor 4.00 dioctyl 1.00 Bisimidazylat 1.00 Phenylbenzmidazolsulfonsäure 0.50 Titanium dioxide 0.50 zinc oxide 0.50 C _12-15 alkyl benzoates 2.00 Butyleneglycoldicaprylat / dicaprate 4.00 phenyltrimethicones 2.00 PVP hexadecene copolymer 0.50 glycerin 3.00 Vitamin E acetate 0.50 2-aminopyridine 0.10 curcumin 0.20 Koncyl - L® q.s. methylparaben q.s. phenoxyethanol q.s. ethanol 3.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 19 Hydro dispersion

Wt .-% Natriumcarbomer 0.20 Xanthan gum 0.30 Anisotriazin 1.50 dioctyl 2.00 4-methylbenzylidenecamphor 4.00 octocrylene 4.00 zinc oxide 1.00 C _12-15 alkyl benzoates 2.50 dicaprylyl 4.00 dicaprylyl 2.00 dimethicone 0.50 Shea butter 2.00 glycerin 7.50 iminopiperidine 0.10 DMDM hydantoin 0.60 Koncyl - L® q.s. methylparaben q.s. phenoxyethanol q.s. ethanol 2.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 20 Hydro dispersion

Wt .-% cetyl alcohol 1.00 Acrylates / C _10-30 alkyl acrylate cross polymer 0.40 Xanthan gum 0.15 butylmethoxydibenzoylmethane 2.00 ethylhexyl triazone 3.00 octocrylene 4.00 Bisimidazylat 0.50 Titanium dioxide 2.00 zinc oxide 3.00 Butyleneglycoldicaprylat / dicaprate 2.00 dicaprylyl 6.00 dimethicone 1.00 octoxyglycerol 1.00 Glycine soy 1.50 Vitamin E acetate 0.25 thiocarbamate 0.30 DMDM hydantoin 0.40 Koncyl-L® q.s. methylparaben q.s. phenoxyethanol q.s. ethanol 1.50 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 21 Hydro dispersion

Wt .-% Polyoxyethylene (20) cetylstearyl ether 0.50 Natriumcarbomer 0.30 Acrylate / C _10-30 Alkyl Acrylate Crosspolymer 0.10 ethylhexylmethoxycinnamate 5.00 Anisotriazin 2.00 dioctyl 2.00 ethylhexyl triazone 4.00 dioctyl 2.00 Phenylbenzmidazolsulfonsäure 3.00 Titanium dioxide 3.00 Butylenglycoldicaprylat / dicaprate 6.00 Phenyl 0.50 PVP hexadecene copolymer 0.50 glycerin 7.50 Carboxy-PTIO potassium 0.25 N ^G -nitro-L-arginine 0.15 DMDM hydantoin 0.20 Koncyl-L® q.s. methylparaben q.s. phenoxyethanol q.s. Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 22 Hydro dispersion

Wt .-% Acrylate / C _10-30 Alkyl Acrylate Crosspolymer 0.10 Xanthan gum 0.50 ethylhexylmethoxycinnamate 8.00 Anisotriazin 2.50 dioctyl 1.00 4-methylbenzylidenecamphor 2.00 octocrylene 2.50 Bisimidazylat 2.00 Titanium dioxide 1.00 zinc oxide 2.00 phenyltrimethicones 2.00 PVP hexadecene copolymer 1.00 octoxyglycerol 0.50 glycerin 2.50 Vitamin E acetate 1.00 L-NIL dihydrochloride 0.60 Koncyl - L® q.s. methylparaben q.s. phenoxyethanol q.s. ethanol 1.00 Perfume q.s. water ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 23 Gel Cream

Wt .-% Acrylate / C _10-30 Alkyl Acrylate Crosspolymer 0.40 Carbomer 0.20 Xanthan gum 0.10 Cetylstearylalkohol 3.00 C _12-15 alkyl benzoates 4.00 Caprylic / capric 3.00 cyclomethicone 5.00 Dimethicone 1.00 2-aminopyridine 0.10 glycerin 3.00 sodium hydroxide q.s. preservation q.s. Perfume q. s. Water, demineralized ad 100.00 AL = L <pH value set to 6.0

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 24 W / O Cream

Wt .-% Lameform® TGI 3.50 glycerin 3.00 Dehymuls® PGPH 3.50 iminopiperidine 0.20 preservative q.s. Perfume q.s. magnesium sulfate 0.6 isopropyl 2.0 dicaprylyl 8.0 Cetylstearylisononanoat 6.0 Water, demin. ad 100.00

The respective components of the oil or water phase are combined, the two Pha combined at 70-75 ° C and homogenized and afterwards on room temp cooled.  

Example 25 W / O / W Cream

Wt .-% glyceryl stearate 3.00 PEG-100 stearate 0.75 behenyl 2.00 Caprylic / capric 8.00 octyldodecanol 5.00 C _12-15 alkyl benzoates 3.00 Carboxy-PTIO potassium 0.50 _MgSO4 0.80 EDTA 0.10 preservation q.s. Perfume q.s. Water, demineralized ad 100.00 AL = L <pH adjusted to 6.0

The components of the oil phase are combined and homogenized, then with the water phase and at a temperature of 80-85 ° C (i.e., in the phase inversions temperature range of the system), then cooled to room temperature (ie out of the phase inversion temperature range of the system).

Claims (5)

1. Use of substances that prevent the NO synthase of warm-blooded Organism unfolds its effect, for the production of cosmetic or dermatological Preparations for the prophylaxis and treatment of inflammatory skin conditions - also atopic eczema and / or skin protection in susceptible, determined tro skin. 2. Use according to claim 1, characterized in that it 0.001-10 wt .-%, particularly preferably 0.01-1% by weight, contained in one or more substances, prevent the NO synthase of the warm-blooded organism ent folds, preferably NO synthase inhibitors, based on the overall composition of Preparations. 3. Use according to claim 1 or 2, characterized in that the substance or substances which prevent the NO synthase of the warm-blooded organism unfolds its effect, is or will be

• a) from the group of substances which inhibits NO synthase (= NO synthase inhibitors or NO synthase inhibitors) and / or
• b) from the group of substances that inhibit or prevent the expression of NO synthase in Warmblü term organism.

4. Use according to claim 3, characterized in that the one or more selected under (a) NO synthase inhibitor is selected from the group or to summarized: Ebselen (2-phenyl-1,2-benzisoselenazol-3 (2H ) -one), canavanine (2-amino-4-guanidinooxybutyric acid), N-acylsphingosine; 2-amino-4-methylpyridine, S-methylisothiourea, citrulline, thiocarbamate, iminopiperidine, dialkyliminopyridoline, 2-aminopyridine or iminopiperidine, 5-hetero-2-iminohexahydroazepine, fluoroacetamidine amino acids, oleic acid], aminoguanidine hemisulphate (CAS no. : [996-19-01]), (±) -2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine hydrochloride (CAS No .: [21463-31-0]) , Benzamide (CAS No .: [55-21-0]), carboxy-PTIO potassium (2- (4-carboxyphenyl) -4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazole -yloxy-3-oxide potassium) (CAS No .: [148819-94-7]), N ^G , N ^G -dimethyl-L-arginine dihydrochloride (CAS No .: [65005-57-4]) , Diphenyleniodonium chloride (CAS No .: [244-54-2]), LN ⁵ - (1-Iminoethyl) ornithine hydrochloride, (CAS No .: [36889-13-1]), L-N6- (1 Iminoethyl) -lysine hydrochloride (CAS No .: [150403-89-7]), 1,5-isoquinolinediol (CAS No: [5154-02-9]), N ^G - monomethyl-L-arginine acetate (CAS -Nr .: (17035-90-4]), N ^G -nitro-L-arginine (CAS No .: [2149-70-4]), N ^G -nitro-L-arginine methyl ester hydrochloride (CAS-No. : (51298-62-5]), 7-nitroindazole (CAS No .: [2942-42-9]), 1H- [1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (CAS No .: [41443- 28-1]), 1- (2-trifluoromethylphenyl) imidazole (CAS No .: [25371-96-4]), (2S, 4R) -4-methyl glutamic acid (CAS No .: [31137-74- 3]), 3-bromo-7-nitroindazole (CAS No .: [74209-34-0]), curcumin (1,7-bis (4-hydroxy-3-methoxyphenyl) -1,6-heptadiene-3 , 5-dione) (CAS No .: [458-37-7]), 6,7-dimethyltetrahydropterin hydrochloride (CAS No .: [167423-51-O]), diphenylene iodonium chloride (CAS No .: [ 4673-26-1]), N-ethyl-N'-phenylguanidine hydrochloride, guanidinoglutaric acid (CAS No .: [73477-53-9]), S-isopropylisothiourea hydrobromide (CAS No .: [4269-97- 0]), N ^G , N ^G -dimethyl-L-arginine hydrochloride, S-methyl-L-thio citrulline hydrochloride, L-NIL dihydrochloride (N ⁶ - (iminoethyl) -L-lysine dihydrochloride) (CAS No .: [159190-45-1]), L-NIO dihydrochloride (N ⁵ - (1-iminoethyl) -L-ornithine dihydrochloride) (CAS No .: [36889-13-1]), L-NMMA citrate (N5- [1-imino (methylamino) methyl] -L-arginine citrate), 7-nitroindole (GAS No .: [2942 -42-9]), 1,4-PBIT dihydrobromide (thiocarbamic acid-1,4-phenylenedi-2,1-ethanediyl ester dihydrobromide) (CAS No .: [157254-60-9]), 1,3-PBIT Dihydrobromide (thiocarbamic acid-1,3-phenylenedi-2,1-ethanediyl ester dihydro bromide), 1- (2-benzoxazolyl) guanidine, nitroguanidine, 1,3-diaminoguanidine, (2-benzothiazolyl) guanidine, 3-bromo- 7-nitroindazole, S-methylthiourea, Norharman, Oregonin, Hirsutanonol. 5. Use according to claim 3, characterized in that the or under (b) or inhibitors of the expression of the inducible NO synthase is selected are from the group ubiquinone Q10, the benzoquinones, dexmethasone (11,16) -9- Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione).